Courage Against Cancer
At Courage Against Cancer (CAC), we believe every patient deserves evidence-based answers to the question: how does fenbendazole actually fight cancer at the cellular level? Originally developed as an antiparasitic medication, fenbendazole has attracted growing scientific curiosity for its poten…
At Courage Against Cancer (CAC), we believe every patient deserves evidence-based answers to the pillar article’s primary question: what is fenbendazole, and why are cancer patients using it? Fenbendazole is an antiparasitic drug, long used in veterinary medicine, that has recently attracted ser…
At Courage Against Cancer (CAC), we believe every patient deserves evidence-based answers to the questions that matter most — including whether fenbendazole has a legitimate place in cancer research conversations. In 2025 and 2026, the scientific dialogue around this repurposed antiparasitic dru…
At Courage Against Cancer (CAC), we believe patients deserve honest, evidence-based information about emerging research. As interest in this antiparasitic drug has surged following the viral Joe Tippens story, the gap between online claims and actual clinical data has become critical to understand.
At Courage Against Cancer (CAC), we believe every patient deserves evidence-based answers to the question: what cancer types has fenbendazole been studied for? Fenbendazole, a broad-spectrum antiparasitic drug used in veterinary medicine for decades, has drawn growing scientific curiosity as a p…
Yes, a limited but growing body of peer-reviewed research exists. Laboratory and preclinical studies have examined fenbendazole’s potential anti-cancer mechanisms — including effects on cell division and glucose metabolism in cancer cells.
Laboratory and preclinical research has most frequently examined fenbendazole in the context of colorectal, lung, pancreatic, and prostate cancers. These cancer types appear most often in cell and animal studies exploring fenbendazole’s potential mechanisms.
At Courage Against Cancer (CAC), we believe every patient deserves honest, compassionate information — especially when a viral story raises life-altering questions. Joe Tippens is an Oklahoma businessman whose dramatic account ignited global interest in repurposed drugs and alternative cancer ap…
At Courage Against Cancer (CAC), we believe patients deserve evidence-based answers to the pillar article primary question: Can repurposed antiparasitic drugs play a meaningful role in colorectal cancer research? Fenbendazole has generated significant public attention, but it isn’t the only benz…
At Courage Against Cancer (CAC), we believe patients deserve evidence-based answers to the pillar article’s primary question — does fenbendazole actually support cancer outcomes — starting with the story that launched the conversation. In 2016, an American named Joe Tippens was diagnosed with te…